A Nanofluorescent Probe for Evaluating the Fluctuation of Aminopeptidase N in Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis

doi:10.1021/acs.analchem.4c03298

	A Nanofluorescent Probe for Evaluating the Fluctuation of Aminopeptidase N in Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis
	Sun, Xiao 1; Wang, Xinlei 1; Fu, Lili 2,3; Wang, Xiaoyan 1,2; Chen, Lingxin1,2,4 ; Huang, Yan 1
发表期刊	ANALYTICAL CHEMISTRY
ISSN	0003-2700
	2024-08-29
卷号	96 期号:36 页码:14639-14649
DOI	10.1021/acs.analchem.4c03298
通讯作者	Chen, Lingxin([email protected]) ; Huang, Yan([email protected])
英文摘要	Aminopeptidase N (APN/CD13) is a widely expressed transmembrane ectoenzyme that is crucial for maintaining normal physiological activities. It exhibits abnormal activity closely associated with hepatic fibrosis and nonalcoholic fatty liver disease (NAFLD). Therefore, there is a high demand for noninvasive detection of aminopeptidase N (APN) in the diagnosis and research of related diseases. Here, we developed a small molecule fluorescent probe, Hcy-APN, which is a fluorescent probe with high sensitivity and selectivity for the detection of APN. Furthermore, we synthesized the fluorescent nanoprobe Hcy-APN@MSN by self-assembling Hcy-APN and mesoporous silica nanoparticles in solution using a combination of molecular probe design and nanofunctionalization strategies. The detection limit of this probe was 1.5 ng/mL. Hcy-APN@MSN exhibits more stable spectral characteristics compared to Hcy-APN and is suitable for detecting APN activity in live cells and mice. Hcy-APN@MSN was utilized for in vivo and intracellular imaging of NAFLD and hepatic fibrosis at different stages, as well as for a systematic assessment of APN levels in the liver. The results confirm an elevation in the expression levels of APN in NAFLD and hepatic fibrosis models. Furthermore, we investigated the inhibitory effect of the APN inhibitor bestatin in nonalcoholic fatty liver and hepatic fibrosis disease models, confirming its regulatory effect on APN levels in cells and in vivo in both disease models. Therefore, this study may offer diagnostic possibilities for detecting NAFLD and hepatic fibrosis.
资助机构	National Natural Science Foundation of China ; Research Initiation Fund of Binzhou Medical University ; Taishan Scholar Project Special Funding
收录类别	SCI
语种	英语
关键词[WOS]	CLINICAL-SIGNIFICANCE ; THERAPEUTIC TARGET ; CD13 ; PREVALENCE ; MANAGEMENT ; BESTATIN ; CELLS
研究领域[WOS]	Chemistry
WOS记录号	WOS:001302851000001
引用统计
文献类型	期刊论文
条目标识符	http://ir.yic.ac.cn/handle/133337/35774
专题	中国科学院海岸带环境过程与生态修复重点实验室中国科学院海岸带环境过程与生态修复重点实验室_海岸带环境工程技术研究与发展中心
通讯作者	Chen, Lingxin; Huang, Yan
作者单位	1.Binzhou Med Univ, Sch Pharm, Yantai 264003, Peoples R China 2.Chinese Acad Sci, Yantai Inst Coastal Zone Res, CAS Key Lab Coastal Environm Proc & Ecol Remediat, Yantai 264003, Peoples R China 3.Shandong Normal Univ, Coll Chem Chem Engn & Mat Sci, Jinan 250014, Peoples R China 4.Shaoxing Univ, Coll Chem & Chem Engn, Shaoxing 312000, Peoples R China
推荐引用方式 GB/T 7714	Sun, Xiao,Wang, Xinlei,Fu, Lili,et al. A Nanofluorescent Probe for Evaluating the Fluctuation of Aminopeptidase N in Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis[J]. ANALYTICAL CHEMISTRY,2024,96(36):14639-14649.
APA	Sun, Xiao,Wang, Xinlei,Fu, Lili,Wang, Xiaoyan,Chen, Lingxin,&Huang, Yan.(2024).A Nanofluorescent Probe for Evaluating the Fluctuation of Aminopeptidase N in Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis.ANALYTICAL CHEMISTRY,96(36),14639-14649.
MLA	Sun, Xiao,et al."A Nanofluorescent Probe for Evaluating the Fluctuation of Aminopeptidase N in Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis".ANALYTICAL CHEMISTRY 96.36(2024):14639-14649.